Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope used in Plus Therapeutics lead radiotherapeutic candidate Rhenium Obisbemeda. The company said the agreement: focus on the production of key radionuclide intermediate aluminum perrhenate and the final processing of cGMP Re-186; and enables expanded, scalable, just-in-time manufacturing to support overall supply chain.
Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.